Skip to content

Study on Gamma Sensory Flicker for Insomnia

Shanxi Key Laboratory of Artificial Intelligence Assisted Diagnosis and Treatment for Mental Disorder

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06322524
Enrollment
37
Registered
2024-03-21
Start date
2021-05-01
Completion date
2022-12-30
Last updated
2024-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Duration, Sleep Onset Latency, Sleep Quality

Keywords

gamma sensory flicke, insomnia, sleep quality, adherence, adverse effect

Brief summary

This prospective observational study enrolled adult volunteers for a sleep quality research study through a questionnaire survey distributed via a WeChat two-dimensional code from May 2021 to April 2022. Participants were exposed to flicker stimulation through a light and sound device for a duration of 8 weeks with daily monitoring.

Detailed description

This prospective observational study enrolled adult volunteers for a sleep quality research study through a questionnaire survey distributed via a WeChat two-dimensional code from May 2021 to April 2022. Participants were exposed to flicker stimulation through a light and sound device for a duration of 8 weeks with daily monitoring. A total of 37 participants underwent polysomnography (PSG) prior to the commencement of the study.

Interventions

DEVICEGamma sensory flicker

participants were exposed to flicker stimulation through a light and sound device, the flicker was 40 Hz.

Sponsors

Shanxi Medical University
CollaboratorOTHER
The First Affiliated Hospital of Shanxi Medical University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

Clinical diagnosis of insomnia according to DSM-5 Cumulative score of ≥7 on the seven-factor components of the Pittsburgh Sleep Quality Index. Sleep disturbances manifest at least three times per week.

Exclusion criteria

Secondary insomnia related to other mental disorders Substance-induced sleep disorders Environmental sleep disorders Sleep apnea syndrome. Stroke patients Insomnia caused by physical diseases, Severe ophthalmic diseases Brain tumors Suspected or confirmed history of alcohol or drug abuse Psychoactive drugs Pregnancy Previous participation in clinical trials within the past three months Epilepsy or family history of epilepsy.

Design outcomes

Primary

MeasureTime frameDescription
Differences in awakening times between the first and eighth weeks8 weeksKeep sleep diaries for the first and eighth weeks of treatment. A comparison of average waking times (times) between the first and eighth weeks of treatment.
Differences in sleep duration between the first and eighth weeks8 weeksKeep sleep diaries for the first and eighth weeks of treatment. A comparison of average sleep duration (hour) between the first and eighth weeks of treatment.
Differences in sleep onset latencies between the first and eighth weeks8 weeksKeep sleep diaries for the first and eighth weeks of treatment. A comparison of average sleep onset latencies (min)between the first and eighth weeks of treatment.
Treatment adherence rate8 weeks (56 days)Participants adhered well to flicker therapy over eight weeks, as measured by the percentage of days they used the device out of the total days they were assigned to use it. Treatment adherence rate = days the patient completed treatment on time/56 days×100%
Patient treatment adherence rate8 weeks (56 days)Participants adhered well to flicker therapy over eight weeks, as measured by the percentage of days they used the device out of the total days they were assigned to use it. Patient treatment adherence rate = sum of all treatment adherence rates / number of patients participating in treatment×100%
Incidence rate of adverse reaction8 weeksDescribe the specific situation of adverse reactions, including types, frequency, severity, and whether they have been relieved. Incidence rate of adverse reactions = number of people experiencing adverse reactions/total number of people participating in treatment x 100%

Secondary

MeasureTime frameDescription
post-sleep efficiency.8 weeksSleep efficiency=total sleep time/total bed rest time x 100% according to the Polysomnography.
pre-sleep efficiency.pre-interventionSleep efficiency=total sleep time/total bed rest time x 100% according to the Polysomnography.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026